9/6/2019 10:47:30 AM
AbbVie Declare Quarterly Cash Dividend Of $1.07/Shr; Record October 15/Payable November 15
9/4/2019 7:10:00 AM
Idera Pharma Announces Immuno-Oncology Clinical Research Collaboration With AbbVie
8/29/2019 8:51:38 AM
AbbVie Discontinues Rovalpituzumab Tesirine Research And Development Program
8/5/2019 8:32:20 AM
AbbVie Submits NDA For Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women
7/26/2019 7:46:50 AM
AbbVie Reports Q2 EPS Of $0.49 On A GAAP Basis; Adj. EPS Of $2.26
7/15/2019 8:09:26 AM
AbbVie Acquires Privately Held Seattle-based Mavupharma; Financial Terms Not Disclosed
7/9/2019 8:10:28 AM
CytomX Says Target Selection Triggers $10 Mln Payment From AbbVie
6/25/2019 9:13:50 AM
AbbVie Gets Positive Recommendation From INESSS For Combination VENCLEXTA With Rituximab As CLL Treatment
6/25/2019 6:45:00 AM
AbbVie To Acquire Allergan In Cash And Stock Transaction For Transaction Equity Value Of About $63 Bln
6/24/2019 8:48:35 AM
AbbVie Says FDA Lifted Partial Clinical Hold Placed On CANOVA Or M13-494
6/20/2019 1:59:50 PM
AbbVie Declares Quarterly Dividend Of $1.07/share, Payable Aug. 15/ Record July 15